COVID-19 Convalescent Plasma Treatment
Conditions
Keywords
convalescent plasma therapy, COVID-19, mortality
Brief summary
To clarify the effects of convalescent plasma therapy on SARS-CoV-2 negative conversion rate during hospital stay and 28-day mortality of severe and life-threatening COVID-19 patients.
Interventions
BIOLOGICALconvalescent plasma
convalescent plasma was get from the patients who recovery from COVID-19
Sponsors
Southeast University, China
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. \> 18 years of age; 2. laboratory-confirmed diagnosis of COVID-19; 3. respiratory failure requiring advanced respiratory support (i.e. high flow nasal cannula\[HFNC\], noninvasive mechanical ventilation \[NIV\], and invasive mechanical ventilation \[IMV\]).
Exclusion criteria
* no
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 28-day mortality | 28 days | the mortality from ICU admission to 28 days after admission |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SARS-CoV-2 negative conversion rate | up to 60 days | SARS-CoV-2 viral shedding |
Countries
China
Outcome results
None listed